PubMed Health⌕ Search

Biomedical subjects

D Lietti

Publications and source records attributed to D Lietti.

5 recordsLinked to original sources

[Vasculitis associated with connectivitis].

A great number of vasculitis in childhood is associated with Rheumatic disease. Vascular lesions involve small vessels of various organs. These are described in systemic lupus erythematosus, juvenile rheumatoid arthritis, dermatomyositis, scleroderma, mixed connective tissue disease, Behçet syndrome, Sjögren syndrome.

Adolescent↗

[Therapy of vasculitis in children].

Therapy of vasculitis syndromes varies considerably according to different forms and gravity. Mild cases often heal spontaneously. In other cases, when the causal factors are known, the removal of the offending antigen or the treatment of an underlying primary disease are sufficient to obtain remission. In the vasculitis syndromes, in which the causal factors are unknown, therapy is based on various associations of nonsteroidal antiinflammatory drugs, antiplatelet drugs, anticoagulants, corticosteroids and cytotoxic drugs, depending on the type, extention and gravity of disease. In most severe systemic necrotizing vasculitis, therapy with corticosteroids and cytotoxic drugs must be protracted for months, with inevitable side-effects, particularly severe in children. Pulse therapy with intravenous bolus of high doses of methylprednisolone seems to offer a new valid therapeutic approach, but is still under investigation. Plasmapheresis may be successful in acute and grave forms. High dose intravenous gammaglobulin therapy is indicated in the prevention of coronary involvement of Kawasaki disease. In this review these problems and therapeutic regimes suggested by different Authors are discussed, with particular attention to their application in childhood.

Adolescent↗

[Treatment using immucytal in children with recurrent respiratory infections: an Italian multicenter experience].

120 children, 71 male and 49 female, aged between 2 years and 15 years (mean 6.15 +/- 3.52 years) with recurrent respiratory infections, were treated with Immucytal, an immunomodulator of bacterial origin, based on membrane proteoglycan fractions plus bacterial ribosomes. The children, selected on the basis of the previous year's clinical score, were treated according to a random design with either Immucytal or placebo, using the same dosage of one puff per nostril plus one puff in the oropharyngeal cavity three times a day, as follows: 1st month: two weeks' treatment, one week wash out, one week's treatment. 2nd, 3rd, 4th months: two weeks' treatment, two week's wash out. Monthly throughout the treatment period the frequency and severity of airway infections episodes were assessed using the same score as for admission. Blood chemistry test, immunological assays (circulating Ig, lymphocyte subpopulations, Merieux Multitest in vivo blastization test) and respiratory tests (spirometry using a pneumotachigraph) were done before and after the treatment. 118/120 children completed treatment; the two dropouts were in the placebo group, one for compliance and the other because of headaches. Respiratory symptoms improved significantly in the actively treated children already from the first month, but not in the placebo group. This improvement consisted of reduction of the respiratory infectious episodes in both the upper and lower airways. No changes were noted in respiratory function parameters. From the immunological viewpoint, there were significant rises in serum IgA and IgM and enhanced skin response tot he Multitest; there was no change in the percentages of different circulating lymphocyte subpopulations.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗

[Chylothorax in a newborn infant].

A case of chylothorax in newborn is described. A the fifteenth day a sudden respiratory distress for chylothorax has appeared. A continuous drainage, after thoracenteses, has been placed; the clinic course has been favourable and, at five day, we have started with MCT feeding.

Chylothorax↗